Eris Lifesciences announced its financial results for the fiscal year ended March 31, 2026, reporting a consolidated revenue of ₹3,129 crore, an increase of 8% year-on-year. The company’s EBITDA margin stood at a strong 36%, with EPS growth of 34% from continuing operations. The Insulins and GLP-1 franchise was a key growth driver, delivering 32% growth. The company also highlighted its strategic investments in expanding manufacturing capabilities and its focus on high-growth specialty areas.
Strong Financial Performance in FY26
Eris Lifesciences Limited has reported robust financial performance for the fiscal year ended March 31, 2026. The company achieved a consolidated operating revenue of ₹3,129 crore, marking an 8% year-on-year growth. This was accompanied by a consolidated EBITDA margin of 36% and a 34% growth in Earnings Per Share (EPS) from continuing operations.
Key Growth Drivers
A significant highlight for the year was the strengthening of the company’s insulin franchise, which demonstrated meaningful progress in the diabetes care category. The strategically important RHI Cartridge segment saw a threefold expansion in market share, increasing from 8% in April 2024 to 25% by the year-end. Across the broader RHI and Glargine market, the company’s share increased from 9% to 16%, underscoring its successful acquisition thesis and execution capabilities in the complex biologics business.
Strategic Investments and Future Outlook
The company also established an early lead in the GLP-1 therapy, securing a rank of #1 by sales volume and #2 by sales value in the injectable segment post the loss of exclusivity for Semaglutide. With in-house manufacturing set to commence in Q2 FY27, Eris Lifesciences is well-positioned to strengthen its market position and operating margins. Underpinning the Injectable Diabesity journey is the Bhopal Biologics facility, an integrated biologics platform designed to provide a sustainable competitive advantage. The company also announced strategic investments of approximately ₹400 crore to elevate its technology and manufacturing capabilities, aiming to capitalize on Biologics and Injectable opportunities across domestic and international markets.
Domestic Formulations Business Performance
Across its Domestic Branded Formulations business, the Dermatology franchise continued to outperform the market, reinforcing its position as a key growth driver. While Oral Anti-Diabetic (OHA) and Cardiac portfolios faced temporary headwinds, the company remains confident in restoring growth momentum in FY27, supported by a strong pipeline of new product launches. The company also exited the Trade Generics segment, sharpening its portfolio and capital allocation priorities, with its Domestic Branded Formulations business delivering an industry-leading EBITDA margin of 37%.
Source: BSE
